RALEIGH, N.C., Jan. 7, 2026 /PRNewswire/ — LabConnect, the world’s most agile central laboratory solutions partner, today announced the opening of its new corporateRALEIGH, N.C., Jan. 7, 2026 /PRNewswire/ — LabConnect, the world’s most agile central laboratory solutions partner, today announced the opening of its new corporate

LabConnect Establishes New Global Headquarters in Raleigh-Durham Area

RALEIGH, N.C., Jan. 7, 2026 /PRNewswire/ — LabConnect, the world’s most agile central laboratory solutions partner, today announced the opening of its new corporate headquarters in Raleigh, North Carolina, strengthening its footprint in the rapidly growing Research Triangle region, a leading center for Contract Research Organizations (CROs), biotechnology, and pharmaceutical companies. The new office will serve as a strategic base for executive leadership, commercial, operational, and technology teams as LabConnect continues to support an expanding portfolio of complex clinical trials worldwide.

Raleigh Durham and the Research Triangle region have emerged as one of the most dynamic life sciences ecosystems in the country, powered by top-tier research universities, a highly skilled workforce, and a dense network of CROs, biotech firms, and pharmaceutical companies. LabConnect’s presence in the region will enhance collaboration with sponsors and CRO partners, accelerate innovation in central lab services, and create new opportunities to pilot advanced sample management, data integration, and technology-enabled solutions close to our clients.

“With this new Raleigh office, we are exactly where our customers are making some of their most important decisions about drug development,” said Wes Wheeler, Chief Executive Officer of LabConnect. “RDU has become one of the world’s most important centers for pharmaceutical innovation, and establishing a stronger corporate presence here allows us to partner even more closely with our clients, attract exceptional talent, and help speed the development of new medicines for patients in need.”

The Raleigh corporate office will complement LabConnect’s seven global operational locations which are adjacent to its partner laboratories supporting: North America, Latin America, Europe and the UK, Australia, China, and ultimately South Korea. The co-location of LabConnect’s operational facilities and its regional partners enables the company to better align scientific, operational, and data capabilities with the needs of emerging and large biopharmaceutical customers.

LabConnect plans to grow the Raleigh office in the coming years, with additional commercial leadership, project management, scientific operations, technology, and data science personnel. The investment reflects the company’s commitment to building a modern, collaborative workplace that leverages the strengths of the RDU market while maintaining its global, asset light operating model and flexible partner lab network.

About LabConnect 

LabConnect is redefining central laboratory services as a technology-driven partner for pharmaceutical and biotechnology companies. Our decentralized network model provides sponsors with access to the industry’s most comprehensive global testing menu, supported by advanced sample tracking, data management, and expert consulting services. With an asset light approach spanning functional service provider solutions, specialty testing, and ancillary support, we deliver scalability and efficiency beyond the limits of traditional laboratory ownership. By building the lab network of the future, LabConnect accelerates the development of life-changing therapies with greater precision, flexibility, and speed. Follow us on LinkedIn and learn more at www.labconnect.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/labconnect-establishes-new-global-headquarters-in-raleigh-durham-area-302655587.html

SOURCE LabConnect

Market Opportunity
Areon Network Logo
Areon Network Price(AREA)
$0.01742
$0.01742$0.01742
-0.40%
USD
Areon Network (AREA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Myriad Moves: Traders Bet on Zcash Rebound, But Aren't Buying Another Bitcoin All-Time High

Myriad Moves: Traders Bet on Zcash Rebound, But Aren't Buying Another Bitcoin All-Time High

Top markets on Myriad this week include predictions on a new Bitcoin all-time high, Ethereum’s next move, and whether Zcash will bounce back.
Share
Coinstats2026/01/09 05:17
Non-Consensual AI Nudes: Governments Confront the Alarming Grok-Generated Flood on X

Non-Consensual AI Nudes: Governments Confront the Alarming Grok-Generated Flood on X

BitcoinWorld Non-Consensual AI Nudes: Governments Confront the Alarming Grok-Generated Flood on X San Francisco, January 2025 – A disturbing technological phenomenon
Share
bitcoinworld2026/01/09 06:35
3 Paradoxes of Altcoin Season in September

3 Paradoxes of Altcoin Season in September

The post 3 Paradoxes of Altcoin Season in September appeared on BitcoinEthereumNews.com. Analyses and data indicate that the crypto market is experiencing its most active altcoin season since early 2025, with many altcoins outperforming Bitcoin. However, behind this excitement lies a paradox. Most retail investors remain uneasy as their portfolios show little to no profit. This article outlines the main reasons behind this situation. Altcoin Market Cap Rises but Dominance Shrinks Sponsored TradingView data shows that the TOTAL3 market cap (excluding BTC and ETH) reached a new high of over $1.1 trillion in September. Yet the share of OTHERS (excluding the top 10) has declined since 2022, now standing at just 8%. OTHERS Dominance And TOTAL3 Capitalization. Source: TradingView. In past cycles, such as 2017 and 2021, TOTAL3 and OTHERS.D rose together. That trend reflected capital flowing not only into large-cap altcoins but also into mid-cap and low-cap ones. The current divergence shows that capital is concentrated in stablecoins and a handful of top-10 altcoins such as SOL, XRP, BNB, DOG, HYPE, and LINK. Smaller altcoins receive far less liquidity, making it hard for their prices to return to levels where investors previously bought. This creates a situation where only a few win while most face losses. Retail investors also tend to diversify across many coins instead of adding size to top altcoins. That explains why many portfolios remain stagnant despite a broader market rally. Sponsored “Position sizing is everything. Many people hold 25–30 tokens at once. A 100x on a token that makes up only 1% of your portfolio won’t meaningfully change your life. It’s better to make a few high-conviction bets than to overdiversify,” analyst The DeFi Investor said. Altcoin Index Surges but Investor Sentiment Remains Cautious The Altcoin Season Index from Blockchain Center now stands at 80 points. This indicates that over 80% of the top 50 altcoins outperformed…
Share
BitcoinEthereumNews2025/09/18 01:43